BMC Cancer (Dec 2023)

Multi-omics integrative modelling for stereotactic body radiotherapy in early-stage non-small cell lung cancer: clinical trial protocol of the MONDRIAN study

  • Stefania Volpe,
  • Mattia Zaffaroni,
  • Gaia Piperno,
  • Maria Giulia Vincini,
  • Maria Alessia Zerella,
  • Federico Mastroleo,
  • Federica Cattani,
  • Cristiana Iuliana Fodor,
  • Federica Bellerba,
  • Tiziana Bonaldi,
  • Giuseppina Bonizzi,
  • Francesco Ceci,
  • Marta Cremonesi,
  • Nicola Fusco,
  • Sara Gandini,
  • Cristina Garibaldi,
  • Davide La Torre,
  • Roberta Noberini,
  • Giuseppe Petralia,
  • Lorenzo Spaggiari,
  • Konstantinos Venetis,
  • Roberto Orecchia,
  • Monica Casiraghi,
  • Barbara Alicja Jereczek-Fossa

DOI
https://doi.org/10.1186/s12885-023-11701-9
Journal volume & issue
Vol. 23, no. 1
pp. 1 – 7

Abstract

Read online

Abstract Background Currently, main treatment strategies for early-stage non-small cell lung cancer (ES-NSCLC) disease are surgery or stereotactic body radiation therapy (SBRT), with successful local control rates for both approaches. However, regional and distant failure remain critical in SBRT, and it is paramount to identify predictive factors of response to identify high-risk patients who may benefit from more aggressive approaches. The main endpoint of the MONDRIAN trial is to identify multi-omic biomarkers of SBRT response integrating information from the individual fields of radiomics, genomics and proteomics. Methods MONDRIAN is a prospective observational explorative cohort clinical study, with a data-driven, bottom-up approach. It is expected to enroll 100 ES-NSCLC SBRT candidates treated at an Italian tertiary cancer center with well-recognized expertise in SBRT and thoracic surgery. To identify predictors specific to SBRT, MONDRIAN will include data from 200 patients treated with surgery, in a 1:2 ratio, with comparable clinical characteristics. The project will have an overall expected duration of 60 months, and will be structured into five main tasks: (i) Clinical Study; (ii) Imaging/ Radiomic Study, (iii) Gene Expression Study, (iv) Proteomic Study, (v) Integrative Model Building. Discussion Thanks to its multi-disciplinary nature, MONDRIAN is expected to provide the opportunity to characterize ES-NSCLC from a multi-omic perspective, with a Radiation Oncology-oriented focus. Other than contributing to a mechanistic understanding of the disease, the study will assist the identification of high-risk patients in a largely unexplored clinical setting. Ultimately, this would orient further clinical research efforts on the combination of SBRT and systemic treatments, such as immunotherapy, with the perspective of improving oncological outcomes in this subset of patients. Trial registration The study was prospectively registered at clinicaltrials.gov (NCT05974475).

Keywords